Department of General Surgery Department, The second hospital of Jilin University, Changchun, 130041, China.
Sci Rep. 2024 Oct 20;14(1):24645. doi: 10.1038/s41598-024-76783-2.
Patients with gastric cancer (GC) are more susceptible to coronavirus disease 2019 (COVID-19), which further worsens their already challenging prognosis. However, there are no effective treatment options for these patients. Lentinan is a potent bioactive component with antiviral and antitumor effects. We hypothesized that lentinan might exert powerful pharmacological effects in patients with GC and COVID-19. In this study, a prognostic model of patients with GC/COVID-19 was constructed and used to apply a network pharmacology approach to reveal biological functions, drug targets, and molecular mechanisms of the action of lentinan against GC/COVID-19. Clinical analysis revealed key prognostic genes in patients with GC/COVID-19. The results of network pharmacology analysis suggested that the therapeutic effect of lentinan on GC/COVID-19 mainly involves the modulation of several neutrophil-related biological processes, as well as the nucleotide-binding and oligomerization domain-like receptor and interleukin-17 signaling pathways. In addition, C-X-C motif chemokine ligand 8, vascular endothelial growth factor A, ribonuclease 3, and F2 were identified as key genes of lentinan against GC/COVID-19. Key prognostic genes were identified in patients with GC/COVID-19 through the construction of a prognostic model. Pharmacological functions and signaling pathways of lentinan against GC/COVID-19 were revealed. These included the regulation of neutrophils and NOD-like receptor signaling pathways. The findings provide the first published evidence of the potential value of lentinan as a complementary therapy for GC/COVID-19.
胃癌（GC）患者更容易感染 2019 年冠状病毒病（COVID-19），这进一步恶化了他们本已严峻的预后。然而，这些患者目前没有有效的治疗选择。香菇多糖是一种具有抗病毒和抗肿瘤作用的强效生物活性成分。我们假设香菇多糖可能对 GC 和 COVID-19 患者发挥强大的药理作用。在这项研究中，构建了 GC/COVID-19 患者的预后模型，并应用网络药理学方法来揭示香菇多糖治疗 GC/COVID-19 的生物学功能、药物靶点和作用机制。临床分析揭示了 GC/COVID-19 患者的关键预后基因。网络药理学分析的结果表明，香菇多糖对 GC/COVID-19 的治疗效果主要涉及对几个中性粒细胞相关生物过程的调节，以及核苷酸结合和寡聚结构域样受体和白细胞介素-17 信号通路。此外，C-X-C 基序趋化因子配体 8、血管内皮生长因子 A、核糖核酸酶 3 和 F2 被确定为香菇多糖治疗 GC/COVID-19 的关键基因。通过构建预后模型，确定了 GC/COVID-19 患者的关键预后基因。揭示了香菇多糖治疗 GC/COVID-19 的药理作用和信号通路，包括对中性粒细胞和 NOD 样受体信号通路的调节。这些发现为香菇多糖作为 GC/COVID-19 辅助治疗的潜在价值提供了首次发表的证据。
